Indocyanine green (ICG) fluorescent cholangiography during laparoscopic cholecystectomy using RUBINA™ technology: preliminary experience in two pediatric surgery centers

Ciro Esposito1 · Daniele Alberti2 · Alessandro Settimi1 · Silvia Pecorelli2 · Giovanni Boroni2 · Beatrice Montanaro2 · Maria Escolino1

Received: 7 March 2021 / Accepted: 6 June 2021 / Published online: 6 July 2021 © The Author(s) 2021

Abstract

Background  Recently, we reported the feasibility of indocyanine green (ICG) near-infrared fluorescence (NIRF) imaging to identify extrahepatic biliary anatomy during laparoscopic cholecystectomy (LC) in pediatric patients. This paper aimed to describe the use of a new technology, RUBINA™, to perform intra-operative ICG fluorescent cholangiography (FC) in pediatric LC.

Methods  During the last year, ICG-FC was performed during LC using the new technology RUBINA™ in two pediatric surgery units. The ICG dosage was 0.35 mg/Kg and the median timing of administration was 15.6 h prior to surgery. Patient baseline, intra-operative details, rate of biliary anatomy identification, utilization ease, and surgical outcomes were assessed.

Results  Thirteen patients (11 girls), with median age at surgery of 12.9 years, underwent LC using the new RUBINA™ technology. Six patients (46.1%) had associated comorbidities and five (38.5%) were practicing drug therapy. Pre-operative workup included ultrasound (n = 13) and cholangio-MRI (n = 5), excluding biliary and/or vascular anatomical anomalies. One patient needed conversion to open surgery and was excluded from the study. The median operative time was 96.9 min (range 55–180). Technical failure of intra-operative ICG-NIRF visualization occurred in 2/12 patients (16.7%). In the other cases, ICG-NIRF allowed to identify biliary/vascular anatomic anomalies in 4/12 (33.3%), including Moynihan’s hump of the right hepatic artery (n = 1), supravescicular bile duct (n = 1), and short cystic duct (n = 2). No allergic or adverse reactions to ICG, post-operative complications, or reoperations were reported.

Conclusion  Our preliminary experience suggested that the new RUBINA™ technology was very effective to perform ICG-FC during LC in pediatric patients. The advantages of this technology include the possibility to overlay the ICG-NIRF data onto the standard white light image and provide surgeons a constant fluorescence imaging of the target anatomy to assess position of critical biliary structures or presence of anatomical anomalies and safely perform the operation.

Keywords  Indocyanine green · Fluorescence · Cholangiography · Technology · Cholecystectomy · Children

Despite widespread implementation of laparoscopic cholecystectomy (LC) in the pediatric population [1, 2], serious complications such as bile duct injury (BDI) and conversion to open continue to be ongoing occurrences [3, 4]. Though infrequent, BDI may cause significant patient morbidity as serious injuries often require complex reconstructive surgery, with variable long-term outcomes [5, 6].

The reported prevalence of BDI following LC ranges from 0 to 7% in early reports [7]. LC seems to be associated with a higher incidence of BDI than previous reports of open cholecystectomy, usually resulting from poor visualization/misinterpretation of anatomic structures [6–8]. Possible explanations include variant anatomy of the biliary tract, obesity, recurrent cholecystitis/cholangitis with resultant adhesions to surrounding structures, fibrosis and distorted anatomy plus failure to obtain an operative cholangiogram, inadequate dissection, injudicious use of cautery or clip placement, or the limited surgical experience [7, 9].
10. Literature, however, continues to indicate the primary cause of BDI is an error in visual perception of the anatomy in 71–97% of cases [11].

This finding has prompted surgeons to search for reliable methods to avoid BDI while performing LC. The Critical View of Safety (CVS) has been described as a preventive measure to decrease the risk of injury to extrahepatic bile ducts [12]. The use of intra-operative cholangiography (IOC) has been recommended to help prevent misinterpretation of biliary anatomy, though its routine use is debated [6, 13]. More recently, indocyanine green fluorescent cholangiography (ICG-FC) has been adopted as a valid alternative to routine IOC for anatomic delineation of the extrahepatic biliary tract in the adult population [11, 14–16].

We reported the feasibility of ICG near-infrared fluorescence (NIRF) imaging to obtain detailed anatomical mapping of extrahepatic biliary structures during LC in the pediatric population as well [17–19]. We also standardized modality of applications of ICG-NIRF, such as dosage and timing of administration, in the pediatric patients [20].

This paper aimed to describe the use of a new technology, RUBINA™, to perform intra-operative ICG-FC during pediatric LC.

**Materials and methods**

**Patient selection**

Patients undergoing LC at two divisions of Pediatric Surgery from January 2020 to January 2021, received intra-operatively ICG-FC using the new technology RUBINA™. All the surgical procedures were performed by three senior surgeons in the two centers.

Inclusion criteria were patients < 18 years old with a history of symptomatic biliary disease (chronic cholecystitis, symptomatic cholelithiasis) as well as acute cholecystitis and cholangitis.

Exclusion criteria included patients who were pregnant or those allergic to iodide or shellfish or those with inadequate documentation regarding ICG-FC use or those needing conversion to open surgery.

The study was approved by the appropriate Institutional Review Board (IRB) at each institution.

**Operative technique**

Patients were admitted the day before surgery to give the ICG injection. A vial of ICG (25 mg) was diluted with 10 mL of sterile water. Once reconstituted, the ICG solution was injected via the intravenous route using a dosage of 0.35 mg/Kg. The median timing of administration was 15.6 h prior to surgery (range 8–20). Following the administration, patients were monitored for any signs of allergic reaction to the dye.

The surgical procedure was performed using IMAGE 1 S™ RUBINA™ system, manufactured by KARL STORZ SE & CO. KG, Tuttingen, Germany. This system is composed of OPAL1® NIR/ICG, a camera head for ICG-NIRF imaging in combination with POWER LED RUBINA™ and TIPCAM®1 RUBINA™, a high-resolution laparoscope with two distally integrated video chips for ICG-NIRF imaging, direction of view 30°, and diameter of 10 mm. A four-trocar laparoscopic cholecystectomy was performed in all cases. After trocar placement and induction of pneumoperitoneum, the ICG-NIRF was activated by pushing a button on the camera head and allowed real-time fluorescent visualization of extrahepatic biliary structures before dissection of the Calot’s triangle. The RUBINA™ components offer various new modes for visualizing the ICG-NIRF signal. In overlay mode, the ICG-NIRF data are overlapped onto the standard white light image to generate an overlay image (Fig. 1a). Depending on your preferences and application, the ICG-NIRF data can be displayed as a green or blue overlay. In the monochromatic mode, the ICG-NIRF signal alone is displayed in white on a black background to achieve the greatest possible differentiation (Fig. 1b). Finally, the intensity map mode displays the intensity of the ICG-NIRF signal using a color scale in an overlay image (Fig. 1c). The specific view mode can be selected in the menu on the camera head. We
preferentially adopted the overlay mode to perform ICG-FC in all cases. In fact, using the overlay of ICG-NIRF signal onto the standard white light image provided by RUBINA™, we adopted NIRF imaging throughout the entire operation during the dissection, without the need to switch between standard camera views to those with ICG-NIRF to more definitively identify the biliary tree anatomy, as happened using the existing IMAGE1 S™ camera platform.

LC was performed by obtaining the critical view of safety (CVS) in all cases. Use of ICG-FC was very helpful to easily detect the cystic duct (CD), the common hepatic duct (CHD), the CD–CHD junction, and the common biliary duct (CBD) and did not require any additional ports or instrumentation (Figs. 2 and 3). The CD was clipped using 5-mm clip appliers with two clips proximal from CBD take off and one to two clips distally. The cystic artery was slowly cauterized using hook electrocautery or clipped and divided. The gallbladder was then removed from the gallbladder fossa with hook electrocautery and extracted through the umbilical trocar’s orifice. The liver bed was then examined for hemostasis.

The ICG-FC view was also helpful during the removal of the gallbladder allowing to identify the dissection plane between the gallbladder and undersurface of the liver. Finally, the anatomy was reidentified, confirming that the CBD was uninjured. In most cases, a drain was routinely placed in the hepatic fossa for at least 12 h postoperatively, according to the surgeon’s personal preference. Trocars’ orifices were closed using resorbable stitches.

The steps of the operative technique are shown in Video 1.

**Data collection**

Patient baseline, intra-operative details, rate of biliary anatomy identification, utilization ease, and surgical outcomes were assessed.

**Results**

Thirteen patients (11 girls and 2 boys), with median age at surgery of 12.9 years (range 6.5–18), underwent LC and received ICG-FC using the new RUBINA™ technology. The median body mass index (BMI) was 22.2 kg/m² (range 12.4–34.8). Based upon their BMI, 2 patients were underweight (< 18.5 kg/m²), 7 patients were ideal weight (≥ 18.5–24.9 kg/m²), 1 was overweight (≥ 25–29.9 kg/m²), and 3 were obese (> 30 kg/m²). Indications for surgery included symptomatic cholelithiasis/biliary colic (n=9), prior acute cholecystitis treated nonoperatively (n=3), and chronic cholecystitis (n=1). Six patients (46.1%) had associated comorbidities including drepanocytosis (n=2), epilepsy (n=1), chronic hepatitis B (n=1), hereditary spherocytosis (n=1), Mirizzi syndrome (n=1), and Crigler–Najjar syndrome type II (n=1). Five patients (38.5%) were practicing drug therapy at time of surgery including phenobarbital (n=1), sodium valproate (n=1), and ursodeoxycholic acid (UDCA) (n=5). Pre-operative workup included ultrasound (n=13) and cholangio-MRI (n=5), excluding biliary and/or vascular anatomical anomalies.

Patient baseline is reported in Table 1.

One patient needed conversion to open surgery due to technical challenges and was excluded from the study. The median operative time was 96.9 min (range 55–180). Technical failure of intra-operative ICG-NIRF visualization occurred in 2/12 patients (16.7%), including absence of fluorescence (n=1) and hyperfluorescence of liver background (n=1) (Fig. 4). In the other cases, ICG-enhanced fluorescence imaging allowed to identify biliary/vascular anatomic anomalies in 4/12 (33.3%), including Moynihan or caterpillar hump of the right hepatic
| Patient n | Gender | Age at surgery (years) | Weight (Kg) | BMI (Kg/m²) | Comorbidity                  | Drug therapy at time of surgery | Pre-operative Ultrasound | Pre-operative MRI | Pre-operative diagnosis anatomy variants | Timing administration ICG prior to surgery (hours) |
|-----------|--------|------------------------|-------------|-------------|-------------------------------|---------------------------------|--------------------------|----------------|----------------------------------------|--------------------------------------------------|
| 1         | F      | 13.1                   | 25          | 12.4        | Drepanocytosis, epilepsy      | Sodium valproate, ursodeoxycholic acid (UDCA) | Yes                      | Yes           | No                                      | 8                                                |
| 2         | F      | 7.4                    | 26          | 16.9        | Hereditary spherocytosis      | No                               | Yes                      | Yes           | No                                      | 13                                               |
| 3         | F      | 15.7                   | 45          | 19.2        | No                            | UDCA                             | Yes                      | Yes           | No                                      | 12                                               |
| 4         | F      | 12.9                   | 51          | 19.6        | Drepanocytosis                | Amoxicillin                      | Yes                      | Yes           | No                                      | 13                                               |
| 5         | F      | 6.4                    | 32          | 21.9        | Mirizzi’s syndrome            | UDCA                             | Yes                      | Yes           | No                                      | 14                                               |
| 6         | F      | 12                     | 71          | 27.7        | No                            | No                               | Yes                      | No            | No                                      | 21                                               |
| 7         | F      | 18                     | 87          | 30.1        | No                            | No                               | Yes                      | No            | No                                      | 20                                               |
| 8         | F      | 13                     | 61.2        | 24.5        | No                            | No                               | Yes                      | No            | No                                      | 18                                               |
| 9         | M      | 18                     | 65.5        | 23.2        | No                            | No                               | Yes                      | No            | No                                      | 20                                               |
| 10        | F      | 13                     | 87          | 34.8        | No                            | No                               | Yes                      | No            | No                                      | 18                                               |
| 11        | M      | 17                     | 88.5        | 31.3        | Chronic hepatitis B           | No                               | Yes                      | No            | No                                      | 20                                               |
| 12        | F      | 17                     | 56          | 21.3        | Crigler–Najjar syndrome type II | Phenobarbital                    | Yes                      | Yes           | No                                      | 18                                               |
| 13        | F      | 9                      | 37.5        | 19.1        | No                            | No                               | Yes                      | No            | No                                      | 19                                               |
artery \((n = 1)\), that is a tortuous right hepatic artery producing sinuosity and coming very close to the gallbladder and cystic duct (Fig. 5), supravesicular bile duct \((n = 1)\) (Fig. 6), and short cystic duct \((n = 2)\).

No allergic or adverse reactions to ICG injection, post-operative complications, or reoperations were reported. Patient outcomes are reported in Table 2.

**Discussion**

The primary goal of any surgery is to achieve optimal surgical results. To meet this objective, the visualization and display of significant and critical structures are of crucial importance to the surgical workflow. The rapid development of technology has led to greater insights in the field of minimally invasive surgery (MIS) and, ultimately, to a potentially better outcome for the patient.

As in adults, laparoscopic cholecystectomy (LC) has now become the technique of choice also in the pediatric population [3]. However, despite the improvement in the learning curves of pediatric surgeons, the procedure is not without complications [3]. The most serious complications include biliary tree injuries, usually resulting from poor visualization/misinterpretation of anatomic structures [6–8].

As recently published [17–20], the incorporation of ICG fluorescent cholangiography (FC) into LC has the potential to provide real-time visualization of the extrahepatic biliary tree prior to commencing dissection within the Calot’s triangle. The evolving technologies have recently provided the surgeons perfect camera systems to achieve even better intra-operative visualization.

The new IMAGE1 S™ RUBINA™ components provide surgeons a series of advantages compared with the existing IMAGE1 S™ camera platform. These options include native 4K resolution, offering very good image quality in
both white light and ICG-NIRF modes, and natural color rendition; possibility to adopt 3D technology in 4 K and enhanced 3D quality image compared to previous model; automatic horizon control; laser-free LED light source for white light, and ICG-NIRF providing excitation of ICG and autofluorescence in the near-infrared range, durability and constant light intensity, and control via touch display and footswitch. The OPAL1® ICG-NIRF technology integrated into the RUBINA™ camera platform provides the overlay mode with ICG-NIRF data displayed in green or blue onto the standard white light image or intensity map mode for displaying signal intensity in the overlay image or monochromatic mode for ICG-NIRF signal alone (Fig. 1). In our experience, we preferentially adopted the overlay mode, as the ICG-NIRF data overlapped onto the standard white light image allowed us to keep a constant assessment of anatomy and continuously identify the position of critical biliary structures, while performing the operation without the need to switch between the ICG-NIRF and the standard bright light view.

Use of ICG-FC was very helpful to easily detect the cystic duct (CD), the common hepatic duct (CHD), the CD–CHD junction, the common bile duct (CBD), the right hepatic duct, and accessory hepatic ducts and did not require any additional ports or instrumentation (Figs. 2 and 3). Improved anatomical identification allowed for targeted dissection of the CD and aided to confirm cystic artery versus CD during dissection. We found the use of ICG-FC very useful to orient the surgeon to the location of biliary structures, particularly in the setting of excess adipose tissue overlying the Calot’s triangle, or adhesions resulting from inflammatory processes, or in case of aberrant anatomy.

When performing cholecystectomy, the surgeon must remember that there are many variations from the normal anatomy of the vessels and bile ducts in the Calot’s triangle. Thanks to the use of ICG-FC, we were able to identify anatomy variants in 33.3% of our cases, including Moynihan’s or caterpillar hump of the right hepatic artery, supravesicular bile duct, and short cystic duct.

Numerous variations in origin and branching pattern of right hepatic artery have been reported. In some cases, tortuous right hepatic artery producing sinuosity may come very close to the gallbladder and cystic duct in the form of “caterpillar hump or Moynihan’s hump” [21]. If such a hump is present, the cystic artery in turn is very short (Fig. 5). In this situation right hepatic artery is either liable to be mistaken identified as cystic artery or torn in attempts to ligate the cystic artery [22]. Injury to right hepatic artery leads to ischemic necrosis of right functional lobe of the liver. So, the presence of caterpillar hump should be suspected when an unusually large cystic artery is viewed through the laparoscope [23].

Another debated point is the optimal dosage and timing of administration of ICG to obtain optimal visualization of the extrahepatic biliary tree [24, 25]. We adopted a dosage of 0.35 mg/kg in all cases, and the median time of administration was 15.6 h prior to surgery. Strong fluorescence of the background tissues was visualized intraoperatively in

| Patient | Operative time (minutes) | Intra-operative complications | Technical problems of ICG-NIRF | Intra-operative diagnosis of variant anatomy | Post-operative complications | Allergy and/or reactions to ICG | Conversion to open surgery | Reoperation |
|---------|--------------------------|-------------------------------|-------------------------------|---------------------------------------------|-----------------------------|---------------------------------|-------------------------------|-------------|
| 1       | 95                       | No                            | Hyperfluorescence liver background | No                                        | No                          | No                              | No                            | No          |
| 2       | 145                      | No                            | No                            | Moynihan’s hump                            | No                          | No                              | Yes                           | No          |
| 3       | 180                      | No                            | No                            | Accessory hepato-cystic duct               | No                          | No                              | No                            | No          |
| 4       | 100                      | No                            | No                            | Gallbladder indented in the liver fossa    | No                          | No                              | No                            | No          |
| 5       | 420                      | No                            | No                            | No                                         | No                          | No                              | Yes                           | No          |
| 6       | 55                       | No                            | No                            | No                                         | No                          | No                              | No                            | No          |
| 7       | 78                       | No                            | No                            | No                                         | No                          | No                              | No                            | No          |
| 8       | 115                      | No                            | No                            | Short and angled cystic duct               | No                          | No                              | No                            | No          |
| 9       | 85                       | No                            | No                            | No                                         | No                          | No                              | No                            | No          |
| 10      | 62                       | No                            | No                            | No                                         | No                          | No                              | No                            | No          |
| 11      | 58                       | No                            | No                            | No                                         | No                          | No                              | No                            | No          |
| 12      | 125                      | No                            | Absent fluorescence          | No                                         | No                          | No                              | No                            | No          |
| 13      | 65                       | No                            | No                            | Short cystic duct                          | No                          | No                              | No                            | No          |

Table 2 Patient outcomes
one patient, in whom the ICG administration was performed just 8 h prior to the procedure (Fig. 4). Based upon our experience, we believe that ICG administration should be performed the day before surgery, average 16–18 h prior to the procedure, to obtain better fluorescence contrast between the bile duct and background tissues, thereby enhancing the efficacy of ICG-FC during LC.

It is also important to consider that some drugs can interfere with the ICG mechanism of action. In our series, we reported a technical failure in intra-operative visualization of ICG-NIRF in one patient affected by Crigler–Najjar syndrome type 2, who was in treatment with phenobarbital. In such patient, we observed a weak fluorescence of biliary structures, which did not improve following intra-operative administration of additional ICG solution.

This study has further confirmed that ICG-FC during LC has the potential to increase both patient safety and procedural efficiency via enhancement and optimization of tissue visualization. No post-operative complications occurred in our series. However, conversion from laparoscopic to open cholecystectomy is sometimes mandatory, due to inability to identify anatomy, need to avoid injury, or insurance of patient safety. Furthermore, this technology is very easy to use as ICG-NIRF view can be directly activated by pushing a button on the camera without increased need for staffing or additional supplies in the operative theater, beyond the addition of a NIR-capable laparoscopic equipment.

Regarding the costs to adopt this innovative imaging technology, you need to buy the IMAGE1 S™ RUBINA™ system, including the specific camera head and the light source, and a separate high-resolution scope, TIPCAM®1 RUBINA™, with two distally integrated video chips for ICG-NIRF imaging, manufactured by KARL STORZ SE & CO. KG, Tuttingen, Germany. The cost of the IMAGE1 S™ RUBINA™ system is about 50,000 Eur, whereas the cost of the scope, TIPCAM®1 RUBINA™, is about 5,000 Eur. The ICG dye costs about 40 Eur per vial. So, considering that this technology is easy to use, safe, and versatile, if the operating room is provided with all the equipment needed for ICG-NIRF, it may be adopted in every routine pediatric LC with practically no adjunctive costs except for the ICG vial.

No absolute contraindications exist for the administration of ICG dye, and ICG has been used safely in patients with documented iodine allergy [26, 27]. Risk of an adverse event with ICG is small. Anaphylactoid reaction has been reported at a rate of 0.003%, with a 0.34% overall incidence of mild adverse reactions [26, 27]. We adhere to the general recommendation that ICG not to be used for patients with a shellfish allergy or iodine contrast sensitivity, and we did not experience any adverse reactions with the use of ICG.

Our preliminary experience suggested that the new RUBINA™ technology was very effective to perform ICG-FC during LC in pediatric patients. The advantages of this technology include the possibility to overlay the ICG-NIRF data onto the standard white light image and provide surgeons a constant fluorescence imaging of the target anatomy to assess position of critical biliary structures or presence of anatomical anomalies and safely perform the operation.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00464-021-08596-7.

**Funding** Open access funding provided by Università degli Studi di Napoli Federico II within the CRUI-CARE Agreement.

**Declarations**

**Disclosure** Drs Ciro Esposito, Daniele Alberti, Alessandro Settimi, Silvia Pecorelli, Giovanni Boroni, Beatrice Montanaro, and Maria Escolino declare that they have no conflict of interest or financial ties to disclose.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Holcomb GW 3rd, Morgan WM 3rd, Neblett WW 3rd, Pietsch JB, O’Neill JA Jr, Shyr Y (1999) Laparoscopic cholecystectomy in children: lessons learned from the first 100 patients. J Pediatr Surg 34(8):1236–1240
2. Esposito C, Alicchio F, Giurin I, Perricone F, Ascione G, Settimi A (2009) Lessons learned from the first 109 laparoscopic cholecystectomies performed in a single pediatric surgery center. World J Surg 33(9):1842–1845
3. Mura da Costa K, Saxena AK (2021) Complications in pediatric laparoscopic cholecystectomy: systematic review. Updates Surg 73(1):69–74
4. Esposito C, Gonzalez Sabín MA, Cercione F, Sacco R, Esposito G, Settimi A (2001) Results and complications of laparoscopic cholecystectomy in children. Surg Endosc 15(8):890–892
5. Kohn JF, Trenk A, Kuchta K, Lapin B, Denham W, Linn JG, Haggerty S, Joehl R, Ujiki MB (2018) Characterization of common bile duct injury after laparoscopic cholecystectomy in a high-volume hospital system. Surg Endosc 32(3):1184–1191
6. Flum DR, Delliger EP, Cheadle A, Chan L, Koeppel T (2003) Intraoperative cholangiography and risk of common bile duct injury during cholecystectomy. JAMA 289(13):1639–1644
7. Koirala U, Subba K, Thakur A, Joshi MR, Thapa P, Singh DR, Sharma SK (2011) Biliary complications after laparoscopic cholecystectomy. J Nepal Health Res Coun 9(1):38–43
8. Pesce A, Portale TR, Minutolo V, Scillettta R, Li Destri G, Puleo S (2012) Bile duct injury during laparoscopic cholecystectomy without intraoperative cholangiography: a retrospective study on 1100 selected patients. Dig Surg 29(4):310–314

9. Giger UF, Michel J-M, Opitz I, Inderbitzin DT, Kocher T, Krähenbühl L (2006) Risk factors for perioperative complications in patients undergoing laparoscopic cholecystectomy: analysis of 22,953 consecutive cases from the Swiss Association of Laparoscopic and Thoracoscopic Surgery database. J Am Coll Surg 203(5):723–728

10. Kala S, Verma S, Dutta G (2014) Difficult situations in laparoscopic cholecystectomy. Surg Laparosc Endosc Percutan Tech 24(6):484–487

11. Broderick RC, Lee AM, Cheverie JN, Zhao B, Blitzer RR, Patel RJ, Soltero S, Sandler BJ, Jacobsen GR, Doucet JJ, Horgan S (2020) Fluorescent cholangiography significantly improves patient outcomes for laparoscopic cholecystectomy. Surg Endosc. https://doi.org/10.1007/s00464-020-08045-x (Epub ahead of print)

12. Strasberg SM, Hertl M, Soper NJ (1995) An analysis of the problem of biliary injury during laparoscopic cholecystectomy. J Am Coll Surg 180(1):101–125

13. Dip FD, Asbun D, Rosales-Velderrain A, Lo Menzo E, Simpfendorfer CH, Szomstein S, Rosenthal RJ (2014) Cost analysis and effectiveness comparing the routine use of intraoperative fluorescent cholangiography with fluoroscopic cholangiogram in patients undergoing laparoscopic cholecystectomy. Surg Endosc 28(6):1838–1843

14. Dip F, Roy M, Lo Menzo E, Simpfendorfer C, Szomstein S, Rosenthal RJ (2015) Routine use of fluorescent incisionless cholangiography as a new imaging modality during laparoscopic cholecystectomy. Surg Endosc 29:1621–1626

15. Vlek SL, van Dam DA, Rubinstein SM, de Lange-de Klerk ESM, Schoonmade LJ, Tuynman JB, Meijerink WJH, Ankersmit M (2017) Biliary tract visualization using near-infrared imaging with indocyanine green during laparoscopic cholecystectomy: results of a systematic review. Surg Endosc 31(7):2731–2742

16. Pesce A, Latteri S, Barchitta M, Portale TR, Di Stefano B, Agodi A, Russello D, Puleo S, La Greca G (2018) Near-infrared fluorescent cholangiography–real-time visualization of the biliary tree during elective laparoscopic cholecystectomy. HPB (Oxf) 20(6):538–545

17. Esposito C, Corcione F, Settimi A, Farina A, Centonze A, Esposito G, Spagnuolo M, Escolino M (2019) Twenty-five year experience with laparoscopic cholecystectomy in the pediatric population—from 10 mm clips to indocyanine green fluorescence technology: long-term results and technical considerations. J Laparoendosc Adv Surg Tech A 29(9):1185–1191

18. Esposito C, Settimi A, Del Conte F, Cerulo M, Coppola V, Farina A, Crocettto F, Ricciardi E, Esposito G, Escolino M (2020) Image-guided pediatric surgery using indocyanine green (ICG) fluorescence in laparoscopic and robotic surgery. Front Pediatr 8:314

19. Calabro KA, Harmon CM, Vali K (2020) Fluorescent cholangiography in laparoscopic cholecystectomy and the use in pediatric patients. J Laparoendosc Adv Surg Tech A 30(5):586–589

20. Esposito C, Del Conte F, Cerulo M, Gargiulo F, Izzo S, Esposito G, Spagnuolo M, Escolino M (2019) Clinical application and technical standardization of indocyanine green (ICG) fluorescence imaging in pediatric minimally invasive surgery. Pediatr Surg Int 35(10):1043–1050

21. Sangameswaran K, Rohini Devi M (2017) Surgical importance of caterpillar (Moynihan) hump of right hepatic artery. Int J Anat Res 5:3672–3675

22. Marano L, Bartoli A, Polom K, Bellochi R, Spaziani A, Castagnoli G (2019) The unwanted third wheel in the Calot’s triangle: incidence and surgical significance of caterpillar hump of right hepatic artery with a systematic review of the literature. J Minim Access Surg 15(3):185–191

23. Crist DW, Gadacz TR (1993) Laparoscopic anatomy of the biliary tree. Surg Clin North Am 73(4):785–798

24. Matsumura M, Kawaguchi Y, Kobayashi Y, Kobayashi K, Ishizawa T, Akamatsu N, Kaneko J, Arita J, Kokuo N, Hasegawa K (2021) Indocyanine green administration a day before surgery may increase bile duct detectability on fluorescence cholangiography during laparoscopic cholecystectomy. J Hepatobiliary Pancreat Sci 28(2):202–210

25. Tsutsui N, Yoshida M, Nakagawa H, Ito E, Iwase R, Suzuki N, Imakita T, Ohdaira H, Kitajima M, Yanaga K, Suzuki Y (2018) Optimal timing of preoperative indocyanine green administration for fluorescent cholangiography during laparoscopic cholecystectomy using the PINPOINT(R) endoscopic fluorescence imaging system. Asian J Endosc Surg 11:199–205

26. Chu W, Chennamsetty A, Toroussian R, Lau C (2017) Anaphylactic shock after intravenous administration of indocyanine green during robotic partial nephrectomy. Urol Case Rep 12:37–38

27. Bjerregaard J, Pandia MP, Jaffe RA (2013) Occurrence of severe hypotension after indocyanine green injection during the intraoperative period. A A Case Rep 1(1):26–30

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.